Zhejiang Provincal Hospital of TCM
Welcome,         Profile    Billing    Logout  
 1 Trial 
7 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Huang, Hao
NCT04481841: Head Yuanshi Dian Therapy in Burning Mouth Syndrome

Recruiting
1
290
RoW
oryzanol + vitamin B2 (riboflavin) + vitamin E, head yuanshi dian therapy
Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang Provincial Hospital of TCM, Guiyang Hospital of Stomatology
Burning Mouth Syndrome, Oral Mucosa Disease
02/22
05/22
NCT06184542: Phase I Clinical Trial of Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine

Recruiting
1
460
RoW
DTacP (one-dose booster), DTacP (three-dose primary vaccination), DT (one-dose booster), DTaP (one-dose booster), PENTAXIM (one-dose booster), DTaP (three-dose primary vaccination), PENTAXIM (three-dose primary vaccination)
Institute of Medical Biology, Chinese Academy of Medical Sciences, Sichuan Center for Disease Control and Prevention
Diphtheria, Tetanus, Pertussis
12/24
11/26
Xie, Xiaohong
TCTN, NCT02455141: Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer

Recruiting
3
970
RoW
Epirubicin plus Cyclophosphamide, EC, Taxanes, Taxanes plus Carboplatin
Shanghai Jiao Tong University School of Medicine
Breast Neoplasm
12/22
12/23
NCT06607796: Efficacy and Safety of Intratumoral Toluenesulfonamide (PTS) Injection in Stage IV Driver Gene-Negative NSCLC With/Without Chemoimmunotherapy

Recruiting
3
180
RoW
Toluenesulfonamide (PTS) Intratumoral Injection
Zhou Chengzhi
Lung Cancer
12/26
12/26
NCT06685978: Efficacy and Safety of Xiangjurupining Capsule for Hyperplasia of Mammary Glands

Recruiting
3
430
RoW
Xiang Ju Ru Pi Ning capsule Placebo, Placebo group, Xiang Ju Ru Pi Ning capsule, Experimental group
Tasly Pharmaceutical Group Co., Ltd
Hyperplasia of Mammary Glands
04/26
07/26
NCT06607770: Safety and Efficacy of Cryoablation With Karelizumab and Apatinib for Multiple Lung Cancers

Recruiting
1/2
20
RoW
Karelizumab+Apatinib
Zhou Chengzhi
Lung Cancer
08/26
08/27
NCT06670560: Onco-Respirology Epidemiology Based on Real-world Big Data in Respiratory Medicine

Active, not recruiting
N/A
100000
RoW
Zhou Chengzhi
Respiratory, Epidemiology, Neoplasms
04/26
06/26

Download Options